UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, D.C. 20549

 Form 10-K/A

 (Mark One)

 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the fiscal year ended DECEMBER 31, 2023

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934

 For the transition period from _______________________ to __________________________

 Commission File Number 000-53571

 DOGECOIN CASH, INC.
 (FORMERLY CANNABIS SATIVA, INC.)

 (Exact name of registrant as specified in charter)

 Nevada

 20-1898270

 (State or other jurisdiction of incorporation or organization)

 (I.R.S. Employer Identification No.)

 355 West Mesquite Blvd #C70 Mesquite, NV 89027

 89027

 (Address of principal executive offices)

 (Zip Code)

 If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

 Securities registered pursuant to Section 12(g) of the Act: Common Stock, Par Value $0.001

 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

 Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No

 Note – Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Exchange Act from their obligations under those Sections.

 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

 Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

 Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

 Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its annual report.

 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 Large accelerated filer

 Accelerated filer

 Non-accelerated Filer

 Smaller reporting company

 Emerging growth company

 Indicate by check mark whether the issuer is a shell company (as defined in rule 12b-2 of the Exchange Act). Yes No

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.

 The market value of the voting and non-voting common stock held by non-affiliates was $ 609,112 on June 30, 2023.

 APPLICABLE ONLY TO REGISTRANTS INVOLVED IN BANKRUPTCY
 PROCEEDINGS DURING THE PRECEDING FIVE YEARS

 Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes No

 (APPLICABLE ONLY TO CORPORATE REGISTRANTS)

 Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

 As of March 3, 2024, there were 88,462,526 shares of the issuer's common stock outstanding.

 DOCUMENTS INCORPORATED BY REFERENCE

 List hereunder the following documents if incorporated by reference and the part of the Form 10-K (e.g., Part I, Part II, etc.) into which the document is incorporated: (1) Any annual report to security holders; (2) Any proxy or information statement; and (3) Any prospectus filed pursuant to Rule 424(b) or (c) under the Securities Act of 1933. The listed documents should be clearly described for identification purposes (e.g., annual report to security holders for fiscal year ended December 24, 1980).

 None.

 Explanatory- Note
 This Amendment No. 1 to the Annual Report on Form 10-K for Dogecoin Cash, Inc. (formerly known as Cannabis Sativa, Inc.) for the period ended 12. 31. 2023, originally filed with the Securities and Exchange Commission (the "SEC") on 5.14. 2024 (the "Original Filing") is being filed to correct an omission related to the title of a report that occurred during the drafting of the report. The omitted title of the report was not included in the Original Filing due to an oversight.

 Correction of Omitted Title: "Report of Independent Registered Public Accounting Firm"
 On May 14, 2024, the Company filed its Annual Report on Form 10-K with the Securities and Exchange Commission (the "SEC"). Due to an oversight during the drafting process, the title of the "Report of Independent Registered Public Accounting Firm" was inadvertently omitted. However, the content of the report was properly included within the Form 10-K filing.

 I. Subsequent Events
 Except as described above, this Amendment does not modify or update any other disclosures contained in the Original Filing including the financial statements and related footnotes or reflect events occurring after the date of the Original Filing. This Amendment should be read in conjunction with the Original Filing and subsequent SEC filings made by the Company.

 Additionally, the certifications required by Section 302 and Section 906 of the Sarbanes-Oxley Act of 2002 have been updated and are filed as exhibits to this Amendment.

 We regret any confusion caused by this omission and appreciate the understanding of our investors and stakeholders as we strive to maintain transparency and accuracy in our financial reporting.

 TABLE OF CONTENTS TO ANNUAL REPORT ON FORM 10-K

 YEAR ENDED DECEMBER 31, 2023

 PAGE

 Item 1.

 Business

 Item 1A.

 Risk Factors

 Item 1B.

 Unresolved Staff Comments

 Item 3.

 Legal Proceedings

 Item 4.

 Mine Safety Disclosures

 Item 5.

 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 Item 6.

 Selected Financial Data

 Item 7.

 Management's Discussion and Analysis of Financial Condition and Results of Operations

 Item 7A.

 Quantitative and Qualitative Disclosures About Market Risk

 Item 8.

 Financial Statements and Supplementary Data

 Item 9.

 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 Item 9A.

 Controls and Procedures

 Item 9B.

 Other Information

 Item 10.

 Directors, Executive Officers and Corporate Governance

 Item 11.

 Executive Compensation

 Item 12.

 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 Item 13.

 Certain Relationships and Related Transactions, and Director Independence

 Item 14.

 Principal Accounting Fees and Services

 Item 15.

 Exhibits, Financial Statement Schedules

 SIGNATURES

 FORWARD-LOOKING STATEMENTS

 In addition to historical information, this Annual Report on Form 10-K, including, but not limited to, the sections entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Business," contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. We use words such as "believe", "expect", "anticipate", "project", "target", "plan", "optimistic", "intend", "aim", "will", or similar expressions, which are intended to identify forward-looking statements. You are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, as well as assumptions that if they were to ever materialize or prove incorrect, could cause the results of the Company to differ materially from those expressed or implied by such forward-looking statements. Future events and actual results could differ materially from those set forth in, contemplated by or underlying the forward-looking statements. Forward-looking statements speak only as of the date on which they are made. The Company assumes no obligation and does not intend to update these forward-looking statements for any reason after the date of the filing of this report, to conform these statements to actual results or to changes in our expectations, except as required by law.

 Item 1. Description of Business

 Company Background

 Cannabis Sativa, Inc., formerly named Ultra Sun Corporation, was incorporated under laws of Nevada in November 2005. In 2023, we conducted our operations through our subsidiaries PrestoCorp, Inc. ("PrestoCorp"), a 51% owned Delaware corporation engaged in the telemedicine business.

 We also own 100% of the following subsidiaries: Wild Earth Naturals, Inc. ("Wild Earth"), a corporation re-domiciling to Utah, Eden Holdings LLC ("Eden"), a Virginia limited liability company, Kubby Patent and Licenses, Limited Liability Company ("KPAL"), a Texas limited liability company and Hi Brands International Inc. ("Hi Brands"), a corporation re-domiciling to Utah. Wild Earth, Eden, KPAL, and Hi Brands are currently inactive, but fit into our business strategy as discussed below.

 Our common stock is quoted for trading on the OTCQB Market under the symbol CBDS.

 We currently maintain virtual principal executive offices with our staff and contractors located remotely and typically working out of their homes. Our mailing address is PO BOX 1602, Mesquite, Nevada 89024. Our telephone number is (702) 762-3123.

 Business Strategy

 In 2024, we intend to focus on growth of our telemedicine business while seeking opportunities in brand development and marketing of products and services to the cannabidiol ("CBD") and marijuana industries. We also intend to focus on the consummation of an asset purchase agreement with MJ Harvest, Inc. ("MJ") whereby, if consummated, certain assets of MJ will become 100% owned by the Company. Pursuant to the asset purchase, current shareholders of MJ will receive an approximate 72% interest in the issued and outstanding common shares of the Company.

 Telemedicine

 PrestoCorp ("PrestoDoctor"), offers an online telemedicine platform providing customer access to knowledgeable physicians to obtain a medical marijuana recommendation. PrestoDoctor uses secure video conferencing technology ( to provide a safe and confidential forum for the Doctor patient interview in accordance with state regulations governing issuance of medical marijuana cards. Appointments through PrestoDoctor's website generally take 10-15 minutes and can be scheduled and completed in the same day. This convenience eliminates the need for patients to travel to a clinic. More than 100,000 users have registered to consult with PrestoDoctor's 15+ licensed physicians across the United States. PrestoDoctor currently offers services in Oklahoma, California, Nevada, New York, Missouri, Pennsylvania, Illinois, Iowa, Texas, Louisiana, Ohio, Arkansas, and West Virginia, and is actively targeting expansion into multiple additional states in the coming months.

 Management is currently evaluating opportunities to expand the platform for medical marijuana evaluations into other states and is reviewing other telemedicine applications. The COVID-19 pandemic had been a catalyst for expansion of telemedicine services across the United States, and our existing systems and infrastructure are well suited to providing other similar medical evaluations. The continuing growth of wearable devices and remote monitoring capabilities are further evidence that telemedicine will continue to grow in the coming periods. Growth of the platform to take advantage of these opportunities will require capital for development of new features and capabilities necessary to provide a new service, expansion of personnel and expansion of our contracted physician pool. No assurances can be given that our efforts to expand into new areas and/or provide new services will be successful.

 Brand Development and Product Marketing

 We have assembled a portfolio of brands, products, intangible assets, and expertise to allow research, development, acquisition and licensing of specialized cannabis and CBD related products, including cannabis and CBD formulas, edibles, topicals, strains, recipes, and delivery systems. We plan to engage in marketing and branding within the cannabis and CBD spaces utilizing our existing brands, including our trademark pending "hi" brand, while also seeking out new opportunities for brand aggregation and marketing. In 2023, we were not able to focus on further development of these assets due to limitations on availability of capital and the need to devote our energies to growth in the telemedicine space.

 In 2024, we hope to begin selling products by developing new relationships with manufacturers and distributors. Descriptions of the products/brands we intend to promote include:

 Wild Earth Naturals, Inc. Wild Earth Naturals, Inc. is an herbal skin care products formulation and marketing company that targets the growing natural health care products market in the United States and abroad. We intend to develop and manufacture high-quality, herbal based skin care products providing healthier choices to consumers. We use specialized ingredient mixing processes to produce plant glycerite/mineral herbal blends and oil extractions, which we believe will be unique to the natural health products industry. The ingredients for our products are selected to meet a number of criteria, including, but not limited to, safety, potency, purity, stability, bio-availability, and efficacy. We plan to control the quality of our products beginning at the formulation stage and continuing through controlled sourcing of raw ingredients, manufacturing, packaging, and labeling.

 Hi Brands International Inc. On February 6, 2015, the Company formed Hi Brands International Inc., a Nevada Corporation and wholly owned subsidiary of the Company ("Hi Brands"). Hi Brands entered into a Purchase, Supply and Joint Venture Agreement (the "Agreement"), with Centuria Natural Foods, Inc. ("Centuria") to develop a supply of proprietary CBD (Cannabidiol) Rich Hemp Oil products, but the agreement was never implemented and no business was ever transacted. As a result, Hi Brands International, Inc. has been inactive for the last several years. Although the Hi Brands business has been inactive, the Company believes that there is value in the name and that it may afford a sound outlet for the Company's products as we build work to build out our product portfolio.

 In order to capitalize on the Hi Brands concept, the Company will require capital for a virtual storefront design, online web presence, virtual shopping cart and e-payment capabilities. The concept may also be an attractive base for physical locations, which would then require capital for facilities, physical storefront and interior design, staffing, inventory, and marketing. Until a suitable capital formation plan can be developed and funded, the Hi Brands concept is likely to remain inactive.

 Other Opportunities. In addition to licensing, branding, and technology, we have the ability to offer mainstream medical prescription discount cards, for which the Company will receive a small percentage on each product purchased. This concept has not yet been implemented but is being evaluated by our Telemedicine division for feasibility and return on investment.

 The Company continues to seek the acquisition of companies, intellectual property and other assets that fit within the company's strategic plan of assembling a portfolio of cannabis industry related businesses that have a high growth potential and are accretive to shareholder value.

 Perceived Cannabis Industry Trends

 We believe the cannabis industry will be characterized by the following principal trends: an increased emphasis on high quality products; an increased emphasis on scientific validation for products in the market place; more liberal regulation in regard to cannabis, even under the current administration as states' rights continue to emerge; more consolidation, take-over, and buy-out of companies in the retail, wholesale, and supply side channels; more mainstream companies entering the marketplace; and more funded research on the potential long-term health benefits of cannabis as well as its potential curative properties.

 Vision

 Our vision is to become a highly visible, diversified business promoting superior quality branded products and services and offering effective customer service, fair compensation, sound management and a great working environment. Over time, we plan to expand our branding, research and development, intellectual properties, and licensing activities to reach markets covering telemedicine and consumer education. In order to achieve this vision, we plan to develop brands and branded products which will distinguish our online presence as a source for innovative and effective medicinal cannabis products and cost-effective alternatives for customers seeking quality, affordable natural health products to aid in wellness and appearance.

 Through a long-term commitment to this vision, we hope to become known as a company that is committed to its customers, associates, and communities.

 Products

 Online Telemedicine. Through PrestoDoctor we provide access to knowledgeable physicians for a safe and confidential way to get a medical marijuana recommendation using secure video conferencing technology. Our online telemedicine generates 100% of our revenues.

 Consumer Products. Through December 31, 2023, the products discussed below in this section are conceptual and have produced no significant revenues. We had intended to pursue the strategy described below in 2023, but lack of capital largely shifted our strategic implementation plans to 2024. In 2024, we expect to work on building a product catalogue as we begin testing the market through online sales of products, including:

 Lozenges, utilizing our proprietary formula, offer rapid relief of throat irritation. Based upon preliminary results, our lozenges generally take effect within a period of five to 15 minutes. In addition to the lozenges, we have other forms of edibles under consideration.

 Recover Deep Penetrating Healing Balm is a fast-acting organic anti-inflammatory pain reliever for sore muscles, joints, arthritic and back pain.

 Trauma Cream was developed with a blended infusion of cannabinoids and THC, including Arnica for its numbing effect.

 Face Garden is an antioxidant, moisturizing cream for the face. Face Garden is thought to firm the skin and reduce puffiness and wrinkles, while restoring the skins natural glow and supple appearance.

 Body Garden is a moisturizing body lotion designed to relieve itchy dry skin and protect against sun damage.

 Lip Garden is an emollient balm that we believe can assist with healing of the lips while keeping them supple and moist.

 Branded Clothing and Merchandise. We also intend to offer Wild Earth Naturals and "hi" branded men's and women's fashion tee shirts and sweatshirts from suppliers, as well as caps and coffee mugs through the Company's www.cbds.com website.

 Objectives

 Our current strategy is to continue to promote and grow the telemedicine business under our PrestoDoctor brand, while also focusing on the start-up and ramp up of new branding, licensing, and product sales opportunities, and we will seek strategic corporate and product acquisitions.

 Marketing & Distribution

 Market Conditions in the Cannabis Industry. Our target markets are located in states that have legalized the production and use of cannabis. Twenty-four states plus the District of Columbia have approved measures to legalize cannabis for adult recreational use. Thirty-eight states, the District of Columbia and five US territories have legalized the use of cannabis for medical use in some form. However, it may take multiple years for a state to establish regulations and for cannabis businesses to begin generating revenue from operations in a given state.

 Non-Infused Products and Merchandise. We launched our www.wildearthnaturals.com website in August 2013 but the site has been largely dormant for several years. In 2024, we intend to use social media to drive traffic to our stronger domains; cbds.com, and cannabissativa.com websites. Wild Earth Naturals is not producing revenue at this time, and once the Company rolls out the brand development and product marketing plan for that consumer products lines fulfillment can be accomplished.

 During 2024, we plan to utilize direct business to business sales, internet advertising, social media marketing, and trade show participation to generate sales leads, orders and to entry into leading retailers and wholesalers throughout the U.S. No assurances can be given that we will be successful in such efforts.

 Infused Products. For cannabis infused products, we intend to develop our customer base through licensing agreements with third party manufacturers who are compliant with state cannabis laws in the states in which they conduct business.

 We plan to build brand awareness by utilizing a mix of social media, trade shows, education efforts, and direct marketing to targeted businesses.

 Geographic Presence. We plan to build brand awareness for our products in states where medical cannabis is legal, and to sell non-infused products throughout the United States.

 Information related to MJ that the Company hopes to acquire through a pending asset purchase agreement

 Information relating to MJ can be found in the Company's post-effective amendment to its registration statement on Form S-4/A filed with the Securities and Exchange Commission on March 21, 2023. The registration was withdrawn in August of 2023.

 Competition

 Cannabis Industry. While we do not currently sell products regulated as cannabis (containing THC), we expect to license our brands and products to businesses that will sell cannabis in states where medicinal or recreational cannabis is legal. Therefore, we look to the participants in the medical and recreational cannabis markets for information on competition.

 We believe the competition in the cannabis market will include numerous cannabis product companies that are fragmented in terms of geographic market coverage, distribution channels and product categories, with many companies taking a state-by-state approach. We believe that competition is principally based upon price, quality, efficacy of products, branding, marketing, customer service, and trade support. We anticipate that large pharmaceutical companies will eventually begin to more aggressively compete in the cannabis product market. These companies and certain larger entities may have broader product lines and/or larger sales volumes than companies such as ours. Larger entities entering this market may have significantly greater financial and other resources available to them and possess extensive manufacturing, distribution and marketing capabilities. We anticipate that many of the larger competitors will be able to compete more effectively due to a greater extent of vertical integration. The entry of larger competitors could have a material adverse effect on our results of operations and financial condition.

 Skin Care. Our competition includes numerous skin care companies that are highly fragmented in terms of geographic market coverage, distribution channels, and product categories. In addition, large pharmaceutical companies compete with us in the skin care market. These larger companies have broader product lines and more substantial sales volumes, greater financial and other resources available to them, and possess extensive manufacturing, distribution and marketing capabilities. Among our more prominent competitors are: Earthly Body, Burt's Bees, Melaleuca and Clarins, all of which have substantially longer track records and greater financial resources and operating efficiencies than we will be able to develop in the near term. As a company with limited capital resources, we believe we will be at a competitive disadvantage until such time as we develop a broad portfolio of products that are known and accepted in the industry, and we are able to demonstrate a history of financial stability. There can be no assurance that we will be able to compete effectively in the market.

 Raw Materials and Suppliers

 Our products are produced using ingredients that we believe to be readily available from several sources. Our suppliers purchase raw materials from a number of different vendors. While we expect the raw materials we use to be readily available in normal times, and the current conflict between Russia and Ukraine have and is expected to continue to disrupt elements of the supply chain. At this time, we cannot determine the effect such disruptions may have on the availability of raw materials in future periods or the impact of such disruptions on our business development strategies.

 Intellectual Property

 We hold certain intellectual property (the "IP") consisting of recipes and process/methods to maximize the cannabinoid concentrations used for manufacture of medical marijuana edibles, including our proprietary lozenge. We also hold rights to a proprietary recipe and process/method to maximize the cannabinoid concentrations to be used to make a salve/ointment containing CBD and Arnica Montana.

 We are also the patent holder for a CTA strain of cannabis. We are continuing to pursue commercialization of the CTA strain, but no assurances can be given that the patented strain will result in development of any commercial products.

 The Company intends to use or license the "hi" brand for skin care products, edibles (infused and non-infused), apparel and branded merchandise.

 Effect of Existing or Probable Governmental Regulations on the Business

 Currently, our products consist of telemedicine services, and we are developing and implementing a business strategy to sell products derived from cannabis plants or products containing THC. Accordingly, while the following discussion on governmental regulation is not directly applicable to the Company today, we may become subject to these regulations in the near future.

 The United States federal government regulates drugs in large part through the Controlled Substances Act, or CSA. Marijuana, which is a form of cannabis, is classified as a Schedule I controlled substance. As a Schedule I controlled substance, the federal Drug Enforcement Agency, or DEA, considers marijuana to have a high potential for abuse with no currently accepted medical use in treatment in the United States (except as disclosed below for epilepsy and related syndromes) and a lack of accepted safety for use of the drug under medical supervision. According to the U.S. federal government, cannabis having a concentration of tetrahydrocannabinol, or THC, greater than 0.3% is marijuana. Cannabis with a THC content below 0.3% is classified as hemp. The scheduling of marijuana as a Schedule I controlled substance is inconsistent with what we believe to be widely accepted medical uses for marijuana by physicians, researchers, patients, and others. Moreover, as of November 30, 2020 and despite the clear conflict with U.S. federal law, 38 states and the District of Columbia have legalized marijuana for medical use, while 24 of those states and the District of Columbia have legalized the adult-use of cannabis for recreational purposes. As further evidence of the growing conflict between the U.S. federal treatment of cannabis and the societal acceptance of cannabis, the FDA on June 25, 2018 approved Epidiolex. Epidiolex is an oral solution with an active ingredient derived from the cannabis plant for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. This is the first FDA-approved drug that contains a purified substance derived from the cannabis plant. In this case, the substance is cannabidiol, or CBD, a chemical component of marijuana that does not contain the psychoactive properties of THC.

 Marijuana is largely regulated at the state level in the United States. State laws regulating marijuana are in conflict with the CSA, which makes marijuana use and possession federally illegal. Although certain states and territories of the United States authorize medical or adult-use marijuana production and distribution by licensed or registered entities, under United States federal law, the possession, use, cultivation, and transfer of marijuana and any related drug paraphernalia is illegal. Although our activities currently do not involve any products that contain THC and we are compliant with the applicable state and local laws in states where we do business, should we enter into a new area that involves THC products, strict compliance with state and local laws with respect to cannabis may neither absolve us of liability under United States federal law nor provide a defense to any federal criminal action that may be brought against us.

 In 2013, as more and more states began to legalize medical and/or adult-use marijuana, the federal government attempted to provide clarity on the incongruity between federal law and these state-legal regulatory frameworks. Until 2018, the federal government provided guidance to federal agencies and banking institutions through a series of DOJ memoranda. The most notable of this guidance came in the form of a memorandum issued by former U.S. Deputy Attorney General James Cole on August 29, 2013, which we refer to as the Cole Memorandum.

 The Cole Memorandum offered guidance to federal agencies on how to prioritize civil enforcement, criminal investigations and prosecutions regarding marijuana in all states and quickly set a standard for marijuana-related businesses to comply with. The Cole Memorandum put forth eight prosecution priorities:

 1.

 Preventing the distribution of marijuana to minors;

 2.

 Preventing revenue from the sale of marijuana from going to criminal enterprises, gangs and cartels;

 3.

 Preventing the diversion of marijuana from states where it is legal under state law in some form to other states;

 4.

 Preventing the state-authorized marijuana activity from being used as a cover or pretext for the trafficking of other illegal drugs or other illegal activity;

 5.

 Preventing violence and the use of firearms in the cultivation and distribution of marijuana;

 6.

 Preventing drugged driving and the exacerbation of other adverse public health consequences associated with marijuana use;

 7.

 Preventing the growing of marijuana on public lands and the attendant public safety and environmental dangers posed by marijuana production on public lands; and

 8.

 Preventing marijuana possession or use on federal property.

 On January 4, 2018, former United States Attorney General Sessions rescinded the Cole Memorandum by issuing a new memorandum to all United States Attorneys, which we refer to as the Sessions Memo. Rather than establishing national enforcement priorities particular to marijuana-related crimes in jurisdictions where certain marijuana activity was legal under state law, the Sessions Memo simply rescinded the Cole Memorandum and instructed that "[i]n deciding which marijuana activities to prosecute... with the [DOJ's] finite resources, prosecutors should follow the well-established principles that govern all federal prosecutions." Namely, these include the seriousness of the offense, history of criminal activity, deterrent effect of prosecution, the interests of victims, and other principles.

 Under President Biden, Merrick Garland serves as Attorney General in his administration. It is not yet known whether the Department of Justice under President Biden and Attorney General Garland will re-adopt the Cole Memorandum or announce a substantive marijuana enforcement policy.

 Nonetheless, there is no guarantee that state laws legalizing and regulating the sale and use of marijuana will not be repealed or overturned, or that local governmental authorities will not limit the applicability of state laws within their respective jurisdictions. Unless and until the United States Congress amends the CSA with respect to marijuana (and as to the timing or scope of any such potential amendments there can be no assurance), there is a risk that federal authorities may enforce current U.S. federal law. Currently, in the absence of uniform federal guidance, as had been established by the Cole memorandum, enforcement priorities are determined by respective United States Attorneys.

 We are not aware of other specific governmental regulations that impact our business. We may, however, utilize Chinese vendors for manufacturing a significant portion of the products we intend to sell. To the extent that tariffs are imposed on imported goods manufactured in China, our pricing structure and acceptance in the marketplace may be affected. We may currently stock our products through distributors in foreign countries when appropriate and ship direct from our manufacturer to the foreign distributor when such can be done at a cost savings. We intend to continue to explore ways that we can hold our costs down on the products we sell in order to minimize price sensitivity concerns with our customers.

 Environmental Laws

 We are not aware of any environmental laws that would limit our ability to conduct our current sales and distribution activities in their present form or as we envision them in the near future. As we expand our operations to participate more directly in the cannabis and hemp industries as a distributor of cannabis and hemp products, we may become subject to environmental laws relating to water usage, recycling, waste disposal, and similar regulations that will vary depending on the location of our operations. We intend to address the impact of such environmental regulations when we have a specific use case to evaluate.

 Number of Total Employees and Number of Full Time Employees

 As of May 12, 2024, we have no employees in Cannabis Sativa, Inc. At the end of the year ended December 31, 2023, the Company had independent contractor arrangements with four officers and directors, and three outside service providers. PrestoCorp has seven employees, including two officers of PrestoCorp. Our employees are not represented by unions, and we consider our relationship with our employees to be good. The Company also has relationships with several independent contractors who provide services to the Company on a regular and on-going basis.

 Facilities

 During all of 2023, CBDS operated out of virtual offices maintained by our officers, directors and contractors.

 Our subsidiary PrestoDoctor leases an office in New York. PrestoCorp leased office space through WeWork in New York on a month-to-month basis which ended in April 2022. On April 12, 2022, PrestoCorp signed a new lease in New York with Spaces for a two-year term at $2,590 per month expiring in April 2024.

 Item 1A. Risk Factors

 Not required.

 Item 1B. Unresolved Staff Comments.

 None

 Item 3. Legal Proceedings.

 We are not a party to any material legal proceedings, and, to the best of our knowledge, no such legal proceedings have been threatened against us.

 Item 4. Mine Safety Disclosures.

 Not Applicable.

 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 Market Information

 Our shares of common stock are quoted on the OTCQB Market operated by the OTC Markets Group Inc. of the Financial Industry Regulatory Authority, Inc. ("FINRA") under the symbol "CBDS".

 Holders of Record

 On March 3, 2024, there were 70 holders of record of our common stock, as reported by the Company's transfer agent. In computing the number of holders of record, each broker-dealer and clearing corporation holding shares on behalf of its customers is counted as a single stockholder.

 No Dividends

 No dividends have ever been paid on our securities, and we have no current plans to pay dividends in the foreseeable future.

 Equity Compensation Plan

 During 2017, the Company adopted the Cannabis Sativa, Inc. 2017 Stock Plan which authorized the board of directors to issue up an aggregate of 3,000,000 shares of common stock to allow the Company to compensate employees and consultants from time to time by issuing them shares of Company common stock in return for services provided to the Company rather than paying for the services in cash thereby depleting the cash assets of the Company. As of April 1, 2021, the Company had issued 3,000,000 shares under the 2017 Stock Plan, leaving no shares available for future issuance under the 2017 Plan.

 On September 25, 2020, the Company adopted the Cannabis Sativa 2020 Stock Plan which authorized the Company to utilize common stock to compensate employees, officers, directors, and independent contractors for services provided to the Company. By resolution dated September 25, 2020, the Company authorized up to 1,000,000 shares of common stock to be issued pursuant to the 2020 Stock Plan. This amount was subsequently increased to 2,000,000 shares on January 27, 2021, and all shares under the 2020 Stock Plan were registered with the Securities & Exchange Commission on Form S-8 on January 29, 2021. Registration of the shares in the 2020 Stock Plan allows immediate sale of the shares by the recipient of such shares. As of April 3, 2024, the Company has issued 1,955,575 shares under the 2020 Plan and has 44,425 shares available for future issuance under the 2020 Plan.

 Transfer Agent

 Colonial Stock Transfer Co., Inc., 7840 South 700 East, Sandy, Utah 84070, telephone (801) 355-5740, serves as the transfer agent and registrar for our common stock.

 Recent Sales of Unregistered Securities

 During the year ended December 31, 2022, the Company issued 458,333 shares of preferred stock valued at $100,000 for compensation and 1,306,242 shares of common stock valued at $284,564 to various officers and consultants for compensation. Of the common shares issued during the year for services, 515,625 valued at $112,668 were issued to officers and directors of the Company. The Company also issued 7,089,255 shares of common stock in consideration of notes payable and accrued interest – related parties in the amount of $1,417,851. An officer of the Company also converted 947,764 shares of preferred stock into 947,764 shares common stock and a related party to the company converted 288,223 shares preferred into 5,476,237 shares common.

 During the year ended December 31, 2023, the Company issued 2,450,000 shares of restricted common stock for services in the amount of $88,200 to related parties. The Company also issued 9,900,000 shares of common restricted stock in consideration of notes payable – related parties in the amount of $54,450 and 30,897,674 of common stock of which 6,700,000 was restricted in consideration of notes payable in the amount of $353,176.

 Special Sales Practice Requirements with Regard to "Penny Stocks"

 To protect investors from patterns of fraud and abuse that have occurred in the market for low priced securities commonly referred to as "penny stocks," the SEC has adopted regulations that generally define a "penny stock" to be any equity security having a market price (as defined) less than $5.00 per share, or an exercise price of less than $5.00 per share, subject to certain exceptions. Our stock is subject to the "penny stock" regulations during periods in which the price is below $5.00 per share. During any such periods, broker-dealers selling our common stock are subject to additional sales practices when they sell our stock to persons other than established clients and "accredited investors." For transactions covered by these rules, before the transaction is executed, the broker-dealer must make a special customer suitability determination, receive the purchaser's written consent to the transaction and deliver a risk disclosure document relating to the penny stock market. The broker-dealer must also disclose the commission payable to both the broker-dealer and the registered representative taking the order, current quotations for the securities and, if applicable, the fact that the broker-dealer is the sole market maker and the broker-dealer's presumed control over the market. Monthly statements must be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks. Such "penny stock" rules may restrict trading in our common stock and may deter broker-dealers from effecting transactions in our common stock.

 Item 6. Selected Financial Data

 Not Applicable. The Company is a "smaller reporting company" and not subject to the Selected Financial Data requirement of Item 6.

 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

 The following Management's Discussion and Analysis of Financial Condition and Results of Operations, or MD&A, is intended to help the reader understand the Company, our operations, and our present business environment. MD&A is provided as a supplement to, and should be read in conjunction with, our Consolidated Financial Statements and the accompanying Notes thereto. As discussed in more detail under "Forward-Looking Statements" immediately following this document's Table of Contents, the following discussion contains forward-looking statements that are based on our management's current expectations, estimates, and projections, which are subject to a number of risks and uncertainties. Our actual results may differ materially from those discussed in these forward-looking statements because of the risks and uncertainties inherent in future events.

 Results of Operations

 Fiscal year ended December 31, 2023 compared with fiscal year ended December 31, 2022

 The narrative comparison of the results of operations for the periods ended December 31, 2023 and 2022 are based on the following table.

 Years Ended

 A

 B

 A-B

 2023

 2022

 Change

 Change
 %

 REVENUE

 $
 1,173,830

 $
 1,558,752

 $
 (384,922
)

 -25
 %

 Cost of revenues

 400,746

 597,842

 (197,096
)

 -33
 %

 Cost of sales % of total sales

 %

 %

 %

 Gross profit

 773,084

 960,910

 (181,270
)

 -20
 %

 Gross profit % of sales

 %

 %

 %

 OPERATING EXPENSES

 Professional fees

 288,436

 488,248

 (199,812
)

 -41
 %

 Depreciation and amortization

 151,957

 162,136

 (10,179
)

 -6
 %

 Wages and salaries

 614,736

 847,254

 (232,518
)

 -27
 %

 Advertising

 13,141

 38,471

 (25,330
)

 -66
 %

 General and administrative

 560,666

 828,071

 (267,405
)

 -32
 %

 Total operating expenses

 1,628,936

 2,364,180

 (735,244
)

 -31
 %

 NET LOSS FROM CONTINUING OPERATIONS

 (855,852
)

 (1,403,270
)

 547,418

 %

 Revenue for the fiscal year ended December 31, 2023 decreased 25% compared to the period ended December 31, 2022. Cost of revenues as a percentage of sales decreased 4% between the periods. The reason for the decrease is there is increased competition in the cannabis tele-medicine industry.

 Total operating expenses decreased 31% in 2023 compared with 2022 which trended down as did revenue in the current period. Decreases in professional fees, depreciation and amortization, wages and salaries, advertising, and general and administrative expenses. Professional fees and advertising decreased with continuing efforts at cost reduction. Depreciation and amortization decreased in part due to the discontinuation of GKMP and IBUD. Additional advertising costs were reduced by taking a more focused approach to our target markets. PrestoDoctor managements salaries

 Liquidity and Capital Resources

 Cash used in operating activities was $63,111 in 2023 compared to $235,559 in 2022. In 2023, financing activities provided $59,776, consisting of proceeds from related party notes payable in the net amount of $26,720, and proceeds from convertible notes payable in the amount of $33,056. We ended 2023 with $83,762 in cash on hand.

 The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. We incurred net losses of $1,261,526 and $1,262,837, respectively, for the years ended December 31, 2023, and 2022 and had an accumulated deficit of $82,022,101 as of December 31, 2023. The Company may seek to raise money for working capital purposes through a public offering of its equity capital or through a private placement of equity capital or convertible debt. It will be important for the Company to be successful in its efforts to raise capital in this manner if it is going to be able to further its business plan in an aggressive manner. Raising capital in this manner will cause dilution to current shareholders.

 The amount of cash on hand the Company has does not provide sufficient liquidity to meet all of the immediate needs of our current operations.

 Off Balance Sheet Arrangements

 None

 Item 7A. Quantitative and Qualitative Disclosure About Market Risk

 Not Applicable. The Company is a "smaller reporting company."

 Item 8. Financial Statements

 The following financial statements are being filed with this report and are located immediately following the signature page.

 Financial Statements, December 31, 2023 and 2022
 Reports of Independent Registered Public Accounting Firms
 Consolidated Balance Sheets, December 31, 2023 and 2022
 Consolidated Statements of Operations for the Years Ended December 31, 2023 and 2022
 Consolidated Statements of Changes in Stockholders' Equity from January 1, 2022 through December 31, 2023
 Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022
 Notes to the Consolidated Financial Statements

 Item 9. Changes in and Disagreements with Accountants on Accounts and Financial Disclosure

 None

 Item 9A. Controls and Procedures

 Evaluation of Disclosure Controls and Procedures

 We maintain "disclosure controls and procedures," as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act"), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, or CEO, acting as Chief Financial Officer, or CFO, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable and not absolute assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of disclosure controls and procedures is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 Based on that evaluation, our CEO concluded that our disclosure controls and procedures, including controls and procedures designed to ensure that information required to be disclosed by us is accumulated and communicated to our management (including our CEO), were not effective as of December 31, 2023, and that material information required to be disclosed in this report has not been properly recorded, processed, summarized and reported in a timely manner. In making this determination, we reviewed the material weaknesses in internal control over financial reporting and concluded that the direct involvement of the CEO in all aspects of financial reporting addressed this concern.

 Management Report on Internal Control Over Financial Reporting

 Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company's assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that the Company's receipts and expenditures are being made only in accordance with authorizations of the Company's management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

 Under the supervision of and with the participation of our CEO and with the oversight of the Board of Directors, our management conducted an assessment of the effectiveness of our internal control over financial reporting based on the framework and criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission ("2013 Framework").

 A system of controls, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the system of controls are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

 A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

 We identified material weaknesses in our internal controls over period end cut-off for recording payables, and communications between accounting personnel and management concerning related party and inter-company transactions.

 Based on our evaluation under the framework described above, our management concluded that, due to the material weakness, our internal control over financial reporting was not effective as of December 31, 2023, in accordance with Item 308(a)(3) of Regulation S-K.

 Changes in Internal Controls

 There was no change in our internal control over financial reporting during the quarter ended December 31, 2023, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 Item 9B. Other Information

 None

 Item 10. Directors, Executive Officers and Corporate Governance

 Directors and Executive Officers

 The following table indicates the name, age, term of office and position held by each of our executive officers and directors. The term of office for each officer position is for one year or until his or her successor is duly elected and qualified by the board of directors. The term of office for a director is for one year or until his or her successor is duly elected and qualified by the stockholders.

 Name

 Age

 Incumbency

 Positions Held

 Catherine Carroll

 2013

 Treasurer, Director

 Trevor Reed

 2017

 Robert N. Tankson III

 2020

 David Tobias

 (1)

 CEO, CFO, Secretary and Director

 (1)

 Mr. Tobias has been a director of the Company since 2014, was appointed CEO of the Company on January 9, 2019, became CFO of the Company in the fourth fiscal quarter of 2022.

 Certain biographical information with respect to our executive officers and directors.

 David Tobias. Mr. Tobias has served as President of Wild Earth Naturals, Inc. since May, 2013. He also served as the President of Hemp, Inc. from August 2011 to January 9, 2014. Prior to that, from October 2009 until May 2011, Mr. Tobias held the position of Vice President at Medical Marijuana Inc. where he was instrumental in bringing forward and culminating the merger between CannaBank and Medical Marijuana, Inc. He was earlier Sales Manager for Tulsa custom builder Xcite Homes, from October 2008 to August 2009. Among other qualifications, Mr. Tobias brings to the Board executive leadership experience, including his service as a president of a public company, along with extensive entrepreneurial experience. Mr. Tobias also has a keen sense of the social, political, and economic environment in which the company operates. On January 1, 2019, Mr. Tobias was appointed CEO as a result of the resignation of the former CEO.

 Catherine Carroll. Ms. Carroll has been self-employed since 1984. Ms. Carroll brings an extensive background in accounting, tax preparation, IRS audits, and tax appeals to the company. The Board believes that her insights gained from teaching basic tax preparation classes for 15 years, being an expert witness in tax court; along with her "Life Time Limited Services" teacher's credential in accounting at Delta College in Stockton, CA for 6 years brings the company a valuable perspective. Ms. Carroll had been serving as the CFO, Director and as the Treasurer of the Company since July of 2013. Effective January 30, 2017, she no longer serves as the Company's CFO and will focus her efforts on her positions as Treasurer and Director and keeping the books of the Company.

 Trevor Reed. Mr. Reed has experience as a contractor, builder and cannabis producer. Mr. Reed started his first company 1989, a hardwood flooring company in Santa Fe, New Mexico. That experience led 15-year career as a custom builder of spec homes in New Mexico. Mr. Reed also engaged in small scale land development and commercial construction in New Mexico. In 2008, Trevor moved to Bend, Oregon to be closer to family. During his time in Oregon, Mr. Reed began to learn about the cannabis business and started growing cannabis. Mr. Reed then returned to New Mexico where he became one of the twenty-five licensed producers of cannabis in the State of New Mexico. Mr. Reed's curiosity and tenacity have led him to be the number one cannabis producer in the State of New Mexico for three years in a row. Mr. Reed has also consulted with State regulatory authorities regarding the development of their state cannabis programs. Under Mr. Reed's direction Natural Rx in New Mexico was the first dispensary to become a United Food and Commercial Workers International Union (UFCW) cannabis division member company in 2014. In 2015, Mr. Reed (with partners) established several cannabis dispensaries and cannabis farms in the State of Oregon.

 Robert Tankson. Mr. Tankson worked for Google from 2011 through 2012. After leaving Google in 2012, to pursue his passion for business finance and technology, Rob saw an opportunity in the cannabis space to develop a telemedicine platform. This led to the cofounding of PrestoCorp. The PrestoCorp platform, known as PrestoDoctor, is an online medical cannabis evaluation service that connects patients with cannabis friendly doctors in California, Nevada, New York, Oklahoma and Missouri, with more states in the pipeline. As an executive of PrestoCorp, Rob directed the search for a business partner and ultimately the acquisition of 51% of PrestoCorp by Cannabis Sativa, Inc., in August 2017. Rob continues as an executive of PrestoCorp and is now helping to direct the rapid expansion of the PrestoDoctor platform in the rapidly changing world during and after the Covid-19 pandemic.

 The following is a brief description of the specific experience and qualifications, attributes or skills of each director that led to the conclusion that such person should serve as a director of the Company.

 Mr. David Tobias' knowledge regarding the business of Cannabis Sativa and the implementation of its business plan, provides a critical link between management and the board, enabling the board to provide its oversight function with the benefit of management's perspective of the business.

 Ms. Carroll's knowledge regarding the history, operations and financial condition of Cannabis Sativa provides a critical link between management and the board, enabling the board to provide its oversight function with the benefit of management's perspective of the business.

 Mr. Reed's knowledge of the cannabis industry and his work with state regulators in connection with cannabis legislation brings valuable insight regarding the emerging cannabis industry and regulation to the board of directors.

 Mr. Tankson's experience in the telemedicine space and his position as an executive of PrestoCorp will provide the Board with insights into the company's attempts to grow the telemedicine business as telemedicine becomes an ever more important aspect of life after the COVID-19 pandemic abates.

 Family Relationships

 There are no family relationships between any of our officers and directors.

 Term of Office

 The term of office of each director is one year and until his or her successor is elected at the annual stockholders' meeting and is qualified, subject to removal by the stockholders. The term of office for each officer is for one year and until his or her successor is elected at the annual meeting of the board of directors and is qualified, subject to removal by the board of directors. David Tobias was appointed President of the Company on March 29, 2016, and CEO of the Company on January 9, 2019. Cathy Carroll joined the Board in 2013 and also serves as Treasurer of the Company. Trevor Reed joined the Board in 2017. Robert Tankson joined the Board on January 31, 2020.

 Board of Directors

 Our board of directors consists of four persons. One director, Trevor Reed, is "independent" within the meaning of Rule 5605(a)(3) of the NASDAQ Marketplace. The three that are not independent are officers of the Company or a subsidiary.

 Our board of directors designated an audit committee to be comprised of two independent directors. At this time, the Company only has one independent director. The board also does not have an independent "financial expert" to serve on the audit committee. As a result, the Company is not able to designate an audit committee and the function of the audit committee is currently being performed by the entire Board.

 The board of directors has designated a compensation committee comprised of two independent directors. At this time, the Company only has one independent director. As a result, the Company is not able to designate a compensation committee and the function of the compensation committee is currently being performed by the entire Board.

 The Company's Board of Directors also performs the functions that would customarily be performed by a nominating committee. The Board of Directors does not believe a separate nominating committee is required at this time due to the limited resources of the Company. The Board of Directors has not established policies with regard to the consideration of director candidates recommended by security holders or the minimum qualifications of such candidates.

 Director Meetings

 In 2023, the Company's Board of Directors meetings were held as needed via remote conference call. As a matter of convenience, many of the actions requiring Board approval are conducted telephonically and then documented as consent minutes. All minutes approved by consent require signatures from all directors. Most Board meetings are attended by all of the Directors, and absences, if any, are noted in the minutes. In 2024, meetings will be held at least once quarterly and more often if needed. Actions may also be taken in 2024 without formal meeting by consent signed by each of the directors.

 Communications with Directors

 Stockholders may communicate with the Board of Directors by sending written communications addressed to the Board of Directors, or any individual director, to: Cannabis Sativa, Inc., Attention: Corporate Secretary, Po Box 1602, Mesquite, NV 89024. All communications will be compiled by the corporate secretary and forwarded to the Board of Directors or any individual director, as appropriate. In order to facilitate a response to any such communication, the Company's Board of Directors suggests, but does not require, that any such submission include the name and contact information of the shareholder submitting the communication.

 Code of Ethics

 We have adopted a Code of Ethics and Business Conduct Policy that applies to our executive officers, including our principal executive, financial and accounting officers.

 During the past ten years none of our directors, executive officers, promoters, or control persons was:

 1.

 the subject of any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;

 2.

 convicted in a criminal proceeding or is subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);

 3.

 subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities; or

 4.

 found by a court of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law.

 Section 16(a) Beneficial Ownership Reporting Compliance

 Section 16(a) of the Exchange Act requires our directors and executive officers, and persons who own more than 10 percent of a registered class of our equity securities to file reports of securities ownership and changes in such ownership with the SEC. Officers, directors, and greater than ten percent shareholders also are required by rules promulgated by the SEC to furnish us with copies of all Section 16(a) reports they file. Based solely on a review of the copies of such reports furnished to us, we believe that one of our directors needs to file a Form 3.

 Item 11. Executive Compensation

 The following table sets forth certain information regarding the annual compensation paid to our principal executive officer and principal financial officer in all capacities for the fiscal years ended December 31, 2023 and 2022. No other person served as an executive officer of the Company or received total annual compensation from the Company in excess of $100,000 other than Mr. Tobias, Ms. Carroll, and Mr. Herr as set forth in the table.

 Summary Compensation Table

 Name and Position

 Year

 Salary ($)

 Stock Awards

 Total ($)

 David Tobias, CEO, President, Sec., Director

 2023

 $
 178,125

 $
 --

 $
 --

 2022

 $
 --

 $
 80,000

 $
 80,000

 Brad E. Herr, CFO, Director

 2023

 $
 --

 $
 --

 $
 --

 2022

 $
 25,000

 $
 80,000

 $
 105,000

 Catherine Carroll, Treasurer, Director (1)

 2023

 $
 50,000

 $
 --

 $
 --

 2022

 $
 --

 $
 --

 $
 --

 1.

 Catherine Carroll serves as Treasurer and Director of the Company and maintains the accounting records for the Company.

 We do not have any retirement, pension or profit-sharing plans covering our officers or directors, and we are not contemplating implementing any such plans at this time.

 Director Compensation

 Our directors are issued shares of common stock quarterly for their service on the board of directors. Prior to January 2022, quarterly director compensation was common shares having a market value of $5,000. In January of 2022, quarterly director compensation was changed to common shares having a market value of $2,500.

 Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 The following table sets forth as of February 1, 2023, the number of shares of our common stock, par value $0.001, owned of record or beneficially by each person known to be the beneficial owner of 5% or more of our issued and outstanding shares of common stock, and by each of our officers and directors, and by all officers and directors as a group. On such date, there were 45,566,365 shares of our common stock issued and outstanding. Unless indicated otherwise, the address for any shareholder is the same as the address of the Registrant.

 SHARE OWNERSHIP

 Name and Address of
 Beneficial Owner

 Amount of Direct
 Ownership

 Amount of Indirect
 Ownership

 Total
 Beneficial

 Principal Stockholders

 Common

 Preferred

 Common

 Preferred

 Ownership

 Percentage

 Sadia Barrameda (1)

 1,561,986

 -

 4,753,967

 -

 6,315,953

 13.9
 %

 New Compendium Corp. (2)

 4,753,967

 -

 1,561,986

 -

 6,315,953

 13.9
 %

 David Tobias

 15,180,008

 -

 35,000

 -

 9,015,008

 19,8
 %

 Officers and Directors

 David Tobias (3)

 15,180,008,

 -

 35,000

 -

 9,015,008

 19.8
 %

 Catherine Carroll (4)

 4,315,639

 -

 136,068

 -

 1,251,707

 2.7
 %

 Trevor Reed

 215,530

 -

 -

 -

 215,530

 0.5
 %

 Robert Tankson

 900,562

 -

 -

 -

 77,951

 0.2
 %

 All Officers and Directors as a Group

 20,611,739

 -

 171,068

 -

 10,560,196

 23.2
 %

 (1) Ms. Barrameda is deemed to be the beneficial owner of the 4,753,967 Common Shares owned by New Compendium Corporation as a result of her status as an officer, director and significant shareholder of New Compendium. Ms. Barrameda's address is P.O. Box 1363, Discovery Bay, CA 94505.

 (2) New Compendium Corp. is deemed the beneficial owner of 1,561,986 Common Shares owned by Sadia Barrameda. Ms. Barrameda is an affiliate of New Compendium Corp. New Compendium's address is P.O. Box 1363, Discovery Bay, CA 94505.

 (3) Mr. Tobias is the beneficial owner of 35,000 common shares owned by his wife. Mr. Tobias' address is 355 W. Mesquite Blvd. #C70, Mesquite, NV 89027.

 (4) Ms. Carroll is deemed to be the beneficial owner of 136,068 Common Shares owned by Carroll's Consulting LLC, a company wholly owned by Ms. Carroll. Ms. Carroll's address is 355 W. Mesquite Blvd, #C70, Mesquite, NV 89027.

 Item 13. Certain Relationships and Related Transactions, and Director Independence

 During the year ended December 31, 2022 the Company received short-term advances and proceeds from notes payable from related parties and officers of the Company, including David Tobias and Cathy Carroll, to cover operating expenses. The notes payable bear interest at rates between 5% and 8% per annum. Total notes payable amount to $91,700 and the Company recorded interest expense related to these balances in the amount of $4,228 during 2022. Aggregate accrued interest on the notes payable at December 31, 2022 was $16,374. The principal of the notes were paid down from the amounts due on December 31, 2021, upon the issuance of stock. The remaining principal balance no longer accrues interest.

 During the year ended December 31, 2023, the Company received short-term advances and proceeds from notes payable from related parties and officers of the Company, including David Tobias and Cathy Carroll, to cover operating expenses. The notes payable bear interest at rates between 5% and 8% per annum. Total notes payable amount to $161,170 and the Company recorded interest expense related to these balances in the amount of $3,756 during 2023. Aggregate accrued interest on the notes payable at December 31, 2023 was $20,130. During 2023 $54,450 of principal of the notes were paid down from the amounts due with the issuance of 9,900,000 shares of restricted common stock.

 Approval of Related Party Transactions

 Related party transactions are reviewed and approved or denied by the board of directors of the Company. If the related party to a transaction is a member of the board of directors, the transaction must be approved by a majority of the board that does not include the related party.

 Item 14. Principal Accounting Fees and Services

 The following table presents aggregate fees that were billed or expected to be billed for the fiscal years ended December 31, 2023, and 2022, for professional services rendered by Assure CPA LLC and Elkana Amitai CPA.

 2023

 2022

 Audit Fees

 $
 44,000

 $
 79,500

 Audit-Related Fees

 -

 -

 Tax Fees

 -

 -

 Other Fees

 -

 -

 Total

 $
 44,000

 $
 79,500

 "Audit Fees" represents fees for professional services provided in connection with the audit of our annual financial statements, review of financial statements included in our quarterly reports and related services normally provided in connection with statutory and regulatory filings and engagements and consents.

 "Audit-Related Fees" represent fees for professional services provided in connection with the audit of the financial statements of Presto Corp.

 "Tax Fees" consists of fees for professional services rendered by our principal accountants for tax compliance, tax advice and tax planning.

 "Other Fees" consists of fees for products and services provided by our principal accountants, other than the services reported under "Audit Fees," "Audit-Related Fees," or "Tax Fees" above.

 Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditors

 It is the policy of the Company for all work performed by our principal accountant to be approved in advance by our audit committee. Currently the audit committee does not have the requisite number of independent Board Members. Accordingly, the functions of the audit committee are now being performed by the Full Board. All of the services described above in this Item 14 were approved in advance by our Board of Directors.

 Item 15. Exhibits, Financial Statement Schedules.

 The following documents are included as exhibits to this report.

 (a) Exhibits

 Exhibit
 Number

 SEC
 Reference
 Number

 Title of Document

 Location

 2.1

 Agreement and Plan of Reorganization among Ultra Sun Corporation, Ultra Merger Corp. and Wild Earth Naturals, Inc., dated as of July 12, 2013*

 2.2

 Articles of Merger among Ultra Merger Corp. and Wild Earth Naturals dated as of July 12, 2013

 2.3

 Plan of Merger among Ultra Merger Corp. and Wild Earth Naturals dated as of July 12, 2013

 3.1

 Articles of Incorporation

 Incorporated by Reference (2)

 3.2

 Bylaws

 Incorporated by Reference (2)

 10.1

 Consulting Agreement dated July 12, 2013 between Ultra Sun Corporation and Neil Blosch

 10.2

 Form of Convertible Promissory Notes dated as of April 22, 2013 and Schedule of Notes Beneficially Owned by Officers, Directors and Principal Stockholders as of July 15, 2013

 10.3

 Offer for Purchase and Sale of Business and Assets Between LST Utah, LLC and the Registrant dated August 23, 2013 and related agreements

 Incorporated by Reference (3)

 10.4

 Noncompetition Agreement among the Registrant, David Tobias and LST Utah, LLC dated as of September 27, 2013.

 Incorporated by Reference (3)

 Exhibit
 Number

 SEC
 Reference
 Number

 Title of Document

 Location

 31.1

 Section 302 Certification of Chief Executive Officer

 This Filing

 31.2

 Section 302 Certification of Chief Financial Officer

 This Filing

 32.1

 Section 1350 Certification of Chief Executive Officer

 This Filing

 32.2

 Section 1350 Certification of Chief Financial Officer

 This Filing

 101.INS (4)

 101.SCH (4)

 101.CAL (4)

 101.DEF (4)

 101.LAB (4)

 101.PRE (4)

 *

 The exhibits and schedules to the Agreement and Plan of Reorganization are not included in the foregoing exhibit. The Registrant undertakes to furnish the Commission with supplemental copies of any omitted items on request.

 (1)

 Incorporated by reference to the Company's current report on Form 8-K report filed July 18, 2013.

 (2)

 Incorporated by reference to Exhibits 3(i) and 3(ii) of the Company' s registration statement on Form 10-12G, filed with the SEC on January 28, 2009.

 (3)

 Incorporated by reference to the Company's current report on Form 8-K filed October 25, 2013.

 (4)

 XBRL information is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement or prospectus to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document. These documents will be filed by amendment.

 [SIGNATURES ON NEXT PAGE]

 SIGNATURES

 Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 Cannabis Sativa, Inc.

 (Registrant)

 By:

 /s/ David Tobias

 David Tobias

 Chief Executive Officer, Chief
 Financial Officer and Director

 (Principal Executive Officer and
 Principal Financial Officer)

 Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 /s/ David Tobias

 David Tobias

 Chief Executive Officer, Chief Financial
 Officer and Director
 (Principal Executive Officer and
 Principal Financial Officer)

 /s/ Catherine Carroll

 Catherine Carroll

 /s/ Trevor Reed

 Trevor Reed

 /s/ Robert N. Tankson III

 Robert N. Tankson III

 Page

 FINANCIAL STATEMENTS for the years ended December 31, 2023 and 2022:

 Consolidated balance sheets

 FS - 4

 Consolidated statements of operations

 FS - 5

 Consolidated statements of changes in stockholders' equity

 FS - 6

 Consolidated statements of cash flows

 FS - 7

 Notes to consolidated financial statements

 FS – 8 through FS – 22

 FS-1

 To the stockholders and the board of directors of Cannabis Sativa, Inc.

 Opinion on the Financial Statements

 We have audited the accompanying consolidated balance sheet of Cannabis Sativa, Inc. the "Company") as of December 31, 2022 and the related consolidated statements of operations, changes in stockholders' equity and cash flows for each of the year then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

 The Company's Ability to Continue as a Going Concern

 The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has negative working capital and accumulated deficit. These factors raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 Basis for Opinion

 These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 /s/Assure CPA, LLC.

 Spokane, Washington
 April 17, 2023

 We served as the Company's independent auditor from 2019 to 2023.

 FS-2

 Report of Independent Registered Public Accounting Firm

 To the Board of Directors and Stockholders of Cannabis Sativa, Inc.

 Opinion on the Financial Statements

 We have audited the accompanying the consolidated balance sheets of Cannabis Sativa Inc. and its subsidiaries ("the Company") as of December 31, 2023 and the related statements of operation, changes in stockholders' deficit and cash flows, for the year then ended, and the related notes and schedules (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023, and the results of its operations and its cash flows for the year ended December 31, 2023, in conformity with generally accepted accounting principles in the United States of America.

 Basis for Opinion

 These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 As discussed in Note 10 to the financial statements, the company has revised its financials as of December 31, 2022 and the year then ended.

 Going Concern

 The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, as of December 31, 2023, the Company suffered losses from operations in all years since inception. These and other factors raise substantial doubt about the Company's ability to continue as a going concern. Management's plan regarding these matters is also described in Note 1 to the financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 /s/ Elkana Amitai CPA

 We have served as the Company's auditor since 2024.

 Mitzpe Netofa, Israel

 May 14, 2024

 PCAOB ID 0 681600001

 FS-3

 CONSOLIDATED BALANCE SHEETS

 Revised
 (Note 10)

 2023

 2022

 ASSETS

 Current Assets

 Cash

 $
 83,762

 $
 97,445

 Investment in equity securities, at fair value

 66,000

 379,858

 Right of use asset

 10,232

 —

 Total Current Assets

 159,994

 477,303

 Advances to related party

 75,054

 55,666

 Right of use asset

 —

 38,968

 Property and equipment, net

 2,436

 2,709

 Intangible assets, net

 7,259

 158,943

 Goodwill

 1,775,811

 1,837,202

 Total Assets

 $
 2,020,554

 $

 LIABILITIES AND STOCKHOLDERS' EQUITY

 Current Liabilities

 Accounts payable and accrued expenses

 $
 175,066

 $
 252,611

 Operating lease liability, current

 10,232

 28,736

 Accrued interest - related parties

 20,130

 16,374

 Convertible notes payable

 118,818

 168,500

 Notes payable to related parties

 161,170

 91,700

 Total Current Liabilities

 485,416

 557,921

 Long-term liabilities

 Operating lease liability, long term

 —

 10,232

 Stock payable

 777,747

 418,156

 Total Liabilities

 1,263,163

 986,309

 Commitments and contingencies (Notes 6 and 8)

 Stockholders' Equity:

 Preferred stock $ 0.001 par value; 5,000,000 shares authorized; - 0 - issued and outstanding

 —

 —

 Common stock $ 0.001 par value; 495,000,000 shares authorized; 88,814,037 and 45,566,363 shares issued and outstanding, respectively

 88,815

 45,567

 Additional paid-in capital

 81,392,196

 80,939,618

 Accumulated deficit

 ( 82,083,492
)

 ( 80,691,269
)

 Total Cannabis Sativa, Inc. Stockholders' Equity (Deficit)

 ( 602,481
)

 293,916

 Non-Controlling Interest

 1,359,872

 1,290,566

 Total Stockholders' Equity

 757,391

 1,584,482

 Total Liabilities and Stockholders' Equity

 $
 2,020,554

 $

 The accompanying notes are an integral part of these consolidated financial statements.

 FS-4

 CONSOLIDATED STATEMENTS OF OPERATIONS

 Revised
 (Note 10)

 For the years ended December 31,

 2023

 2022

 Revenues

 $
 1,173,830

 $
 1,558,752

 Cost of Revenues

 400,746

 597,842

 Gross Profit

 773,084

 960,910

 Operating Expenses

 Professional fees

 288,436

 488,248

 Depreciation and amortization

 151,957

 162,136

 Wages and salaries

 614,736

 847,254

 Advertising

 13,141

 38,471

 General and administrative

 560,666

 828,071

 Total Operating Expenses

 1,628,936

 2,364,180

 Loss from Operations

 ( 855,852
)

 ( 1,403,270
)

 Other (Income) and Expenses

 Unrealized (gain) loss on investment

 149,083

 ( 171,318
)

 Employee Retention Credit

 ( 139,970
)

 —

 Impairment of goodwill

 61,391

 —

 Loss on debt settlement

 184,394

 —

 Loss on sale of investment securities

 155,735

 —

 Interest expense

 56,432

 30,885

 Total Other (Income) Expenses, Net

 467,065

 ( 140,433
)

 Loss Before Income Taxes

 ( 1,322,177
)

)

 Income Taxes

 —

 —

 Net Loss

 ( 1,322,917
)

)

 Income (loss) attributable to non-controlling interest - PrestoCorp

 69,306

 ( 47,536
)

 Net Loss Attributable To Cannabis Sativa, Inc.

 $
 ( 1,392,223
)

 $
 ( 1,215,301
)

 Net Loss per Common Share: Basic & Diluted

 $
 ( 0.02
)

 $
 ( 0.03
)

 Weighted Average Common Shares Outstanding:

 Basic & Diluted

 54,554,226

 38,068,401

 The accompanying notes are an integral part of these consolidated financial statements.

 FS-5

 CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022

 Preferred Stock

 Common Stock

 Accumulated

 Non-controlling Interest -

 Shares

 Amount

 Shares

 Amount

 Capital

 Deficit

 Prestocorp

 Total

 Balance - January 1, 2022

 777,654

 $

 30,746,865

 $
 30,748

 $
 79,151,240

 $
 ( 79,475,968
)

 $
 1,338,102

 $
 1,044,900

 Conversion of preferred to common (1:1)

 ( 947,764
)

 ( 948
)

 947,764

 —

 —

 —

 —

 Conversion of preferred to common (19:1)

 ( 288,223
)

 ( 288
)

 5,476,237

 5,476

 ( 5,188
)

 —

 —

 —

 Shares issued for services

 1,306,242

 1,306

 382,804

 —

 —

 384,568

 Shares issued in consideration of notes and interest payable - related parties

 —

 —

 7,089,255

 7,089

 1,410,762

 —

 —

 1,417,851

 Net loss

 —

 —

 —

 —

 —

 ( 1,215,301
)

 ( 47,536
)

)

 Balance - December 31, 2022

 —

 $
 —

 45,566,363

 $
 45,567

 $
 80,939,618

 $
 ( 80,691,269
)

 $
 1,290,566

 $
 1,584,482

 Balance - January 1, 2023

 —

 $
 —

 45,566,363

 $
 45,567

 $
 80,939,618

 $
 ( 80,691,269
)

 $
 1,290,566

 $
 1,584,482

 Common stock issued - note payable conversion

 —

 —

 40,797,674

 40,798

 366,828

 —

 —

 407,626

 Shares issued for services

 —

 —

 2,450,000

 2,450

 85,750

 —

 —

 Net income (loss)

 —

 —

 —

 —

 —

 ( 1,330,483
)

 69,306

 ( 1,261,177
)

 Balance - December 31, 2023

 —

 $
 —

 88,814,037

 $
 88,815

 $
 81,392,196

 $
 ( 82,083,492
)

 $
 1,359,872

 $
 757,391

 The accompanying notes are an integral part of these consolidated financial statements.

 FS-6

 CONSOLIDATED STATEMENTS OF CASH FLOWS

 Revised
 (Note 10)

 For the years ended December 31,

 2023

 2022

 CASH FLOWS FROM OPERATING ACTIVITIES:

 Net loss

 $
 ( 1,322,917
)

 $
)

 Adjustments to reconcile net loss to net cash

 used in operating activities:

 Unrealized loss (gain) on investments

 149,083

 ( 171,318
)

 Interest Expense - Default on Notes

 25,986

 —

 Impairment of goodwill

 61,391

 —

 Interest Payable Forgiven 1800

 ( 4,546
)

 —

 Depreciation and amortization

 151,957

 162,136

 Loss on debt settlement

 184,394

 —

 Loss on sale of investment securities

 155,735

 —

 Stock issued for services

 384,568

 Stock payable for services

 431,853

 418,156

 Note payable issued for services

 85,000

 60,000

 Write off of abandoned equipment

 —

 Changes in Assets and Liabilities:

 Accounts payable and accrued expenses

 ( 73,003
)

 157,580

 Accrued interest - related parties

 3,756

 15,574

 Net Cash Used in Operating Activities

 ( 63,111
)

 ( 235,559
)

 Cash Flows from Investing Activities:

 Cash purchase of equipment

 —

 ( 1,590
)

 Proceeds from sale of stock held for investment

 9,040

 —

 Advances to related party

 ( 19,388
)

 ( 55,666
)

 Net Cash Used in Investing Activities

 ( 10,348
)

 ( 57,256
)

 Cash Flows from Financing Activities:

 Proceeds from related parties notes payable, net

 26,720

 44,040

 Payments on related parties notes payable

 —

 ( 16,340
)

 Proceeds from convertible note payable

 33,056

 168,500

 Net Cash Provided by Financing Activities

 59,776

 196,200

 NET CHANGE IN CASH

 ( 13,683
)

 ( 96,615
)

 CASH AT BEGINNING OF YEAR

 97,445

 194,060

 CASH AT END OF YEAR

 $
 83,762

 $
 97,445

 Supplemental Disclosures of Non Cash Activities:

 Noncash investing and financing activities

 Shares issued in consideration of notes and interest payable - related parties

 $
 30,000

 $
 1,417,851

 Recognition of operating lease liability and right of use asset

 $
 -

 $
 56,595

 Shares issued in consideration of convertible notes payable

 $
 407,626

 $
 -

 The accompanying notes are an integral part of these consolidated financial statements.

 FS-7

 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 For the Years Ended December 31, 2023 and 2022

 1. Organization and Summary of Significant Accounting Policies

 Nature of Business:

 Cannabis Sativa, Inc. (the "Company," "us", "we" or "our") was incorporated as Ultra Sun Corp. under the laws of Nevada in November 2004. On November 13, 2013, we changed our name to Cannabis Sativa, Inc. We operate through several subsidiaries including:

 PrestoCorp, Inc. ("PrestoCorp")

 Wild Earth Naturals, Inc. ("Wild Earth")

 Kubby Patent and Licenses Limited Liability Company ("KPAL")

 Hi Brands, International, Inc. ("Hi Brands")

 Eden Holdings LLC ("Eden").

 PrestoCorp is a 51 % owned subsidiary. Wild Earth, KPAL, Hi Brands, and Eden are wholly owned subsidiaries. At December 31, 2023 and 2022, PrestoCorp is the sole operating subsidiary.

 Our primary operations for the years ended December 31, 2022 and through December 31, 2023 were through PrestoCorp, which provides telemedicine online referral services for customers desiring medical marijuana cards in states where medical marijuana has been legalized. The Company is actively seeking new business opportunities for acquisition and is continually reviewing opportunities for product and brand development through our Wild Earth, Hi Brands, and KPAL subsidiaries.

 Principles of Consolidation:

 The consolidated financial statements include the accounts of Cannabis Sativa, Inc. (the "Company" or "CBDS"), and its wholly-owned subsidiaries and PrestoCorp, a 51 % owned subsidiary. All significant inter-company balances have been eliminated in consolidation.

 Non-controlling Interests:

 Non-controlling interests are portions of entities included in the consolidated financial statements that are not attributable to the Company. Non-controlling interest are identified separately from the Company's stockholders' equity and its net income (loss). Non-controlling interest equity balances include the non-controlling entity's initial contribution at the date of the original acquisition, ongoing contributions, distributions, and percentage share of earnings since inception. The non-controlling interests are calculated based on percentages of ownership.

 FS-8

 Going Concern:

 The Company has an accumulated deficit of $ 82,083,492 at December 31, 2023, which, among other factors, raises substantial doubt about the Company's ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company's ability to generate profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they are due.

 Use of Estimates:

 The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates and assumptions by management affect the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the provision for income taxes and related deferred tax accounts, certain accrued liabilities, revenue recognition, contingencies, and the value attributed to stock-based awards.

 Property and Equipment:

 Property and equipment are recorded at cost. Depreciation is provided for on the straight-line method over the estimated useful lives of the assets. The average lives range from five ( 5) to ten ( 10) years. Leasehold improvements are amortized on the straight-line method over the lesser of the lease term or the useful life. When assets are retired or sold, the costs and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in operations. Maintenance and repairs that neither materially add to the value of the property nor appreciably prolong its life are charged to expense as incurred. Betterments or renewals are capitalized when incurred.

 Fair Value Measurements and Financial Instruments:

 When required to measure assets or liabilities at fair value, the Company uses a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used. The Company determines the level within the fair value hierarchy in which the fair value measurements in their entirety fall. The categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Level 1 uses quoted prices in active markets for identical assets or liabilities, Level 2 uses significant other observable inputs, and Level 3 uses significant unobservable inputs. The amount of the total gains or losses for the period are included in earnings that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date. We measure our investment in equity securities at fair value on a recurring basis. The Company's investments in equity securities are valued using inputs observable in active markets and are therefore classified as Level 1 within the fair value hierarchy.

 The carrying amounts of cash and cash equivalents, convertible debt and balances due to and from related parties approximate fair value given their short-term nature. Goodwill is valued under Level 3 and is analyzed annually for impairment.

 FS-9

 Cash:

 Cash is held at major financial institutions and insured by the Federal Deposit Insurance Corporation (FDIC) up to federal insurance limits. The Company considers all highly liquid investments purchased with an original maturity of three months or less when acquired to be cash equivalents.

 Net Loss per Share:

 Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding for the period and contains no dilutive securities. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of the Company. Potentially dilutive shares are excluded from the calculation of diluted net loss per share because the effect is anti-dilutive. For the years ended December 31, 2023 and 2022, the Company had - 0 - and 50,000 outstanding warrants, respectively, and -0- shares of convertible preferred stock, respectively, that would be dilutive to future periods net income if converted.

 Investments:

 Equity securities of investments in which the Company owns less than 20% and/or has no significant influence are generally measured at fair value with changes in fair value recognized in earnings. Upon sale of an equity security, the realized gain or loss is recognized in earnings.

 Investments in companies in which the Company owns more than 20% and has the ability to exercise significant influence, but do not control, are accounted for under the equity method of accounting. In determining whether significant influence exists, the Company will consider its participation in policy-making decisions and representation on governing bodies. Under the equity method of accounting, the Company's share of the net earnings or losses of the investee are included in earnings. The Company may elect to account for certain equity method investments at fair value whereby the carrying value of the investment is adjusted to fair value at the end of each period and the related change in fair value is recognized in earning. For these investments, the Company's share of the net earnings or losses of the investee are not included in earnings.

 Companies in which the Company holds investments amounting to more than 50% of the voting interests, but less than 100%, and in which the Company has significant influence, are consolidated and other investor interests are presented as non-controlling.

 FS-10

 Revenue Recognition:

 In the year ending December 31, 2023 and 2022, the Company operated one division, the telehealth business operated through PrestoCorp.

 The telehealth division generates revenue based on a per telehealth visit for clients looking to obtain a permit to use marijuana for medical purposes in states that have legalized medical marijuana. Revenues are recognized when the Company satisfies its performance obligation to provide telehealth services upon a referral to a contracted physician. The obligation to perform the referral and the referral are automated and occur at the same time an online client subscribes for the visit and gains access to our network of health care professionals. Recognition of revenue is not dependent on the issuance of a marijuana card since issuance of the card is dependent on health and other factors beyond our control. This initial service is a one-time referral to a physician. Clients may return for other telehealth consultations, typically regarding product recommendations, and such additional physician referrals are provided at an additional cost. The billing and payment processes for each physician referral are automated through our online platform. Revenue is recognized in an amount that reflects the consideration that is received in exchange for each physician referral provided to the client.

 Provision for sales incentives, discounts and returns and allowances, if applicable, are accounted for as reductions of revenue in the period the related sales are recorded. The Company had no warranty costs associated with the sales of its products.

 Intangible Assets and Goodwill:

 Intangible asset amounts represent the acquisition date fair values of identifiable intangible assets acquired. The fair values of the intangible assets were determined by using the income approach, discounting projected future cash flows based on management's expectations of the current and future operating environment. The rates used to discount projected future cash flows reflected a weighted average cost of capital based on our industry, capital structure and risk premiums including those reflected in the current market capitalization. Definite-lived intangible assets are amortized over their useful lives, which have historically ranged from 5 to 10 years. The carrying amounts of our definite-lived intangible assets are evaluated for recoverability whenever events or changes in circumstances indicate that the entity may be unable to recover the asset group's carrying amount. We do not have any indefinite-lived intangible assets recorded from acquisitions.

 Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. Goodwill is not amortized but is tested for impairment annually or more frequently if events or changes in circumstances indicate that the asset may be impaired. The fair value of the reporting unit is evaluated on qualitative factors to determine if the reported value may be impaired. If the qualitative factors indicate a likelihood of impairment, we then evaluate carrying value of the reporting unit based on quantitative factors using the income approach. An impairment charge is recognized for the excess of the carrying value of goodwill for the reporting unit over its implied fair value.

 Advertising Expense:

 Advertising costs are expensed as incurred and are broken out separately in the accompanying consolidated statements of operations.

 FS-11

 Stock-Based Compensation:

 Stock-based payments to employees and non-employees are recognized at their fair values. Compensation expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). Transactions in which goods or services are received for the issuance of shares of the Company's preferred or common stock are accounted for based on the fair value of the common stock issued. The Company currently recognizes compensation costs immediately as our awards are 100% vested at the time of issuance. Forfeitures are recognized upon occurrence.

 Income Taxes:

 The Company utilizes the liability method of accounting for income taxes which requires that deferred tax assets and liabilities be recorded to reflect the future tax consequences of temporary differences between the book and tax basis of various assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Additionally, deferred tax assets are evaluated, and a valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. There can be no assurance that the Company's future operations will produce sufficient earnings so that the deferred tax asset can be fully utilized. The Company currently maintains a full valuation allowance against net deferred tax assets.

 Uncertain tax positions are evaluated in a two-step process, whereby (i) it is determined whether it is more likely than not that the tax positions will be sustained based on the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the related tax authority would be recognized.

 Leases:

 The Company determines if an arrangement is a lease, or contains a lease, at the inception of an arrangement. If the Company determines that the arrangement is a lease, or contains a lease, at lease inception, it then determines whether the lease is an operating lease or finance lease. Operating and finance leases result in recording a right-of-use ("ROU") asset and lease liability on the consolidated balance sheets. ROU assets represent the Company's right of use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. For purposes of calculating operating lease ROU assets and operating lease liabilities, the Company uses the non-cancellable lease term plus options to extend that it is reasonably certain to exercise. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company has elected not to recognize ROU assets and lease liabilities that arise from short-term (12 months or less) leases for any class of underlying asset. The Company has elected not to separate lease and non-lease components for any class of underlying asset.

 FS-12

 Contingencies:

 In determining accruals and disclosures with respect to loss contingencies, the Company evaluates such accruals and contingencies for each reporting period. Estimated losses from loss contingencies are accrued by a charge to income when information available prior to issuance of the financial statements indicates that it is probable that a liability could be incurred, and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.

 Recent Accounting Pronouncement:

 Accounting Standards Updates Adopted

 In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2019-12 Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. The update is to address issues identified as a result of the complexity associated with applying generally accepted accounting principles for certain financial instruments with characteristics of liabilities and equity. The update is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years and with early adoption permitted. Early adoption of this update had no impact on the Company's consolidated financial statements.

 Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption.

 2. Intangibles and Goodwill

 The Company considers all intangibles to be definite-lived assets with lives of 5 to 10 years. Intangibles consisted of the following at December 31, 2022 and 2021:

 2023

 2022

 CBDS.com website (Cannabis Sativa)

 $
 13,999

 $
 13,999

 Intellectual Property Rights (PrestoCorp)

 240,000

 240,000

 Patents and Trademarks (KPAL)

 1,281,411

 1,281,411

 Total Intangibles

 1,535,410

 1,535,410

 Less: Accumulated Amortization

 ( 1,528,151
)

 ( 1,376,467
)

 Net Intangible Assets

 $
 7,259

 $
 158,943

 Amortization expense for each of the years ended December 31, 2023 and 2022 was $ 151,684 and $ 161,863, respectively.

 FS-13

 Amortization of intangibles through 2028 is:

 January 1, 2024 to December 31, 2024

 $
 3,056

 January 1, 2025 to December 31, 2025

 January 1, 2026 to December 31, 2026

 January 1, 2027 to December 31, 2027

 January 1, 2028 to December 31, 2028

 Goodwill in the amount of $ 3,010,202 was recorded as part of the acquisition of PrestoCorp that occurred on August 1, 2017. Cumulative impairment of the PrestoCorp goodwill totals $ 1,234,391 and $ 1,173,000 as of December 31, 2023 and 2022. The balance of goodwill at December 31, 2023 and 2022 was $ 1,775,811 and $ 1,837,202. Goodwill was impaired due to the analysis of PrestoCorp utilizing the discounted cash flow method which supported a present value of $1,775,811. However, since the estimated enterprise value of PrestoCorp is less that the carrying value of the assets, $ 61,391 of impairment write down was required.

 3. Related Party Transactions

 In addition to items disclosed in Notes 6, the Company had additional related party transactions during the years ended December 31, 2023 and 2022.

 For the years ended December 31, 2023 and 2022 officers and board of directors expense was $ 385,532 and $ 491,750, respectively. The Company also had consulting contracts with David Tobias and Cathy Carroll as noted below.

 Historically, the Company has received funds from borrowings on notes payable and advances from related parties and officers of the Company to cover operating expenses. Related parties include the officers and directors of the Company and a significant shareholder holding in excess of 10% of the Company's outstanding shares.

 During the year ended December 31, 2022, David Tobias, the Company's chief executive officer and director, loaned $ 44,040 to the Company for notes payable bearing interest at the rate of 5 % per annum due on December 31, 2022. The Company paid $ 11,340 on this note during 2022. Consulting expense for each of the years ended December 31, 2023 and 2022 was $ 187,500. The last payment of these services were in June of 2022. At December 31, 2023 the Company owes Mr Tobias $ 281,250 in consulting services and $ 18,750 in directors fees which are included in stock payable for a total of $ 300,000. At December 31, 2022 the Company owed Mr. Tobias $ 93,750 in consulting services and $ 6,250 in directors fees which were included in stock payable at December 31, 2022 in the amount of $ 100,000.

 During the year ended December 31, 2022, the Company and Cathy Carroll, director, entered into a note payable for $ 55,000 for compensation due her for services. Ms. Carroll's note bears interest at 5 % per annum and is due December 31, 2022. The note payable totaled $ 60,000 of which $ 5,000 was paid by the Company during 2022.

 During the year ended December 31, 2023, David Tobias, the Company's chief executive officer and director, loaned $ 38,400 to the Company for notes payable bearing interest at the rate of 5 % per annum due on December 31, 2023. The Company paid $ 23,180 on this note during 2023.

 During the year ended December 31, 2023, the Company and Cathy Carroll, director, entered into a note payable for $ 60,000 for compensation due her for services. Ms. Carroll's note bears interest at 5 % per annum and is due December 31, 2023. The note payable totaled $ 109,250 of which $ 5,750 was paid by the Company during 2023.

 Ms Carroll has a consulting agreement with the Company in the amount of $ 12,500 quarterly. For each of the years ended December 31, 2023 and 2022 consulting expense was $ 50,000. Ms Carroll has elected that these payments increase her note payable each quarter along with the amount she receives as a director in the amount of $ 2,500 quarterly.

 During the year ended December 31, 2023, Robert Tankson, one of the company's directors, received from the company payroll compensation equal to $ 37,044 with shares and $ 106,969 with cash.

 FS-14

 The Company also has an outstanding loan in the amount of $ 4,000 to a director of the Company. It accrues interest at 5 % per annum.

 During the years ended December 31, 2023 and 2022, the Company recorded interest expense related to notes payable to related parties at the rates between 5 % and 8 % per annum in the amounts of $ 3,756 and $ 16,374, respectively.

 The following tables reflect the related party note payable balances.

 Related party
 notes

 Accrued
 interest

 Total

 December 31, 2023

 David Tobias, CEO & Director

 $
 47,920

 $
 13,779

 $
 61,699

 New Compendium, greater than 10% Shareholder

 -

 1,906

 1,906

 Cathy Carroll, Director

 109,250

 110,236

 Other Affiliates

 4,000

 1,200

 5,200

 Totals

 $
 161,170

 $
 17,871

 $
 179,041

 Related party
 notes

 Accrued
 interest

 Total

 December 31, 2022

 David Tobias, CEO & Director

 $
 32,700

 $
 12,482

 $
 45,182

 New Compendium, greater than 10% Shareholder

 -

 1,906

 1,906

 Cathy Carroll, Director

 55,000

 55,986

 Other Affiliates

 4,000

 1,000

 5,000

 Totals

 $
 91,700

 $
 16,374

 $
 108,074

 During the year ended December 31, 2022, the Company issued 7,089,255 shares of common stock in settlement of $ 1,214,038 in related party notes payable and $ 203,813 in accrued interest attributable to these notes. The fair value of the shares issued approximated the carrying value of the notes and interest payable.

 During the year ended December 31, 2023, the Company issued 9,900,000 shares of common stock in settlement of $ 17,250 in related party notes payable. The Company also issued 2,450,000 to the officers of Presto valued at $ 88,200 per their contract agreement.

 In the years ended December 31, 2023 and 2022, the Company incurred approximately $- 0 - and $ 26,389, respectively, for consulting services from a nephew of the Company's president. The services for the years ended December 31, 2022 were paid in shares of the Company's common stock. These amounts are included in the statements of operations in general and administrative expenses.

 At December 31, 2023 and 2022, the Company has a balance due from MJ Harvest, Inc., with whom the Company plans to merge, of $ 75,054 and $ 55,666, respectively (see Note 8). The amount is included in advances to related party on the consolidated balance sheets. The funds were advanced to MJ Harvest, Inc. to cover operating expenses.

 FS-15

 4. Investments

 At December 31, 2023 and 2022, the Company owns - 0 - and 8,238,769 shares respectively, of common stock of Medical Cannabis Payment Solutions (ticker: REFG). At December 31, 2023 and 2022, the fair value of the investment in REFG was $- 0 - and $ 12,358, respectively. The Company recognized a loss on the change in fair value of $- 0 - and $ 13,182 during the years ended December 31, 2023 and 2022, respectively. In January 2023, the Company sold all of its holdings in REFG for $ 9,041 and recognized a gain of $ 155,735.

 In 2021, the Company received 1,500,000 shares of common stock and 1,500,000 shares of preferred stock of THC Pharmaceuticals Inc. (ticker: CBDG). The CBDG shares were received as consideration for the sale of the Company's majority interest in iBud and GKMP in the year ended December 31, 2021. On the date of sale, the shares were valued at fair value which was $ 0.20 per share or $ 600,000 in the aggregate. The Company's Chief Executive Officer and Chairman of the Board, David Tobias is a Director of CBDG.

 The Company's investment in CBDG represents 15 % of CBDG's voting shares on a fully diluted basis which, coupled with Mr. Tobias' position as a director and his individual investment in CBDG, results in the Company having significant influence over CBDG. The Company elected to account for its investment in CBDG at fair value because the Company does not intend to hold the investment for a long period of time and the shares are readily marketable. The fair value of the Company's investment at December 31, 2023 and December 31, 2022 was $ 66,000 and $ 367,500 resulting in a gain (loss) of $( 301,500) and $ 184,500 for the change in fair value during the years ended December 31, 2023 and 2022, respectively.

 5. Convertible Notes Payable

 On August 25, 2022 and November 7, 2022, the Company entered into an agreement with 1800 Diagonal Lending, LLC ("Diagonal") whereby the Company issued convertible notes to Diagonal with principal amounts of $ 104,250 and $ 64,250, respectively. The notes bear interest at 10% and have terms of one year when payment of principal and interest is due. After 180 days, the notes are convertible into shares of the Company's common stock the number of which determined by dividing the principal balance outstanding by 65 % of the lowest trading price of the Company's stock during the five previous trading days before the date of the conversion. At December 31, 2023 and 2022 amounts due were $- 0 - and $ 168,500, respectively.

 On January 1, 2023, the Company entered into an agreement with Carolyn Merrill ("Carolyn") whereby the Company issued a convertible note to Carolyn with a principal amount of $ 72,262. As stated in the January 1, 2023, agreement Ms Merrill's contract compensation will also be added to the note for her services through March 31, 2023 in the amount of $ 25,000. On December 19, 2023, $ 11,500 of note payable was converted to 6,700,000 shares common stock which were valued at $ 36,800 resulting in a loss on conversion of $$ 25,300. Note payable at December 31, 2023 is $ 85,762. The note bears interest at 8 % and has a term of one year when payment of principal and interest is due. If payment by S-8 shares the amount paid will be with a 10% discount, if by agreement and paid with restricted stock will be with a 30% discount. Both methods are calculated using the lowest 3 closing prices during the 30 trading days preceding the request for conversion.

 On September 18, 2023, the Company entered into an agreement with Quick Capital, LLC whereby the Company issued a convertible note with a principal amount of $ 33,055. The maturity date is nine months after the issue date, accruing interest at 12 % per annum and can be converted after 180 days from date of issue at a fixed rate of $ 0.01 per share.

 At December 31, 2023 and 2022, accrued interest payable and interest expense on these notes was $ 9,931 and $ 4,546, respectively. Accrued interest payable is included in accounts payable and accrued expenses on the consolidated balance sheet.

 FS-16

 6. Stockholders' Equity

 Change in Authorized Shares

 The Company increased the number of authorized common shares the Company is authorized to issue to 495,000,000 on August 8, 2022. This change in capital structure was approved without a meeting by the consent of the shareholders holding a majority of the common stock outstanding and Articles of Amendment were filed with the State of Nevada.

 Securities Issuances

 During the years ended December 31, 2023, shares of common stock and preferred stock were issued to related and non-related parties for the purposes indicated, as follows:

 Share Issuances in the Year Ended
 December 31, 2023

 Services

 Common

 Preferred

 Value

 Related Parties

 Robert Tankson, Director

 1,029,000

 -

 37,044

 Kyle Powers

 1,421,000

 -

 51,156

 Total related party issuances

 2,450,000

 -

 Non-related party issuances

 -

 -

 -

 Total shares for services

 2,450,000

 -

 Shares issued in consideration of notes - related parties

 9,900,000

 -

 54,450

 Shares issued in consideration of notes and accrued interest - non related parties

 30,897,674

 -

 353,176

 Aggregate Totals

 43,247,674

 -

 $
 495,826

 FS-17

 During the year ended December 31, 2022, shares of common stock and preferred stock were issued to related and non-related parties for the purposes indicated, as follows:

 Share Issuances in the Year Ended
 December 31, 2022

 Services

 Common

 Preferred

 Value

 Related Parties

 David Tobias, Officer, Director

 -

 $
 100,000

 Brad Herr, Officer, Director

 -

 100,168

 Robert Tankson, Director

 28,646

 -

 6,250

 Trevor Reed, Director

 28,646

 -

 6,250

 Total related party issuances

 515,625

 212,668

 Non-related party issuances

 790,617

 -

 171,896

 Total shares for services

 1,306,242

 384,564

 Shares issued in consideration of notes and accrued interest - related parties

 7,089,255

 -

 1,417,851

 Conversion of preferred stock to common (1:1)

 947,764

 ( 947,764
)

 -

 Conversion of preferred stock to common (19:1)

 5,476,237

 ( 288,223
)

 -

 Aggregate Totals

 14,819,498

 ( 777,654
)

 $
 1,802,415

 During the years ended December 31, 2022 David Tobias converted 947,764 of preferred stock into an equal number of common stock in accordance with the terms of the preferred stock.

 During the year ended December 31, 2022, two preferred shareholders agreed to convert an aggregate of 288,223 shares of preferred stock into 5,476,237 shares of common stock. The Company requested the shareholders to convert to simplify its capital structure in contemplation of a proposed merger (see Note 8). The conversion rate was determined on various factors, including recent market price of the Company's common stock and the proposed merger. The conversion rate differed from the original conversion rate resulting in a deemed dividend to the preferred shareholders of $ 25,940 which is the fair value of the common stock issued less the carrying value of the preferred shares that were converted. The dividend had $nil impact on net loss per share for the year ended December 31, 2022.

 Stock payable at December 31, 2022 consists of 1,306,302 preferred shares and 1,469,590 common shares owed to members of the board of directors for directors' fees and contract services. These shares were valued at $ 212,500 based on the fair value of the Company's common stock at the date of board authorization. An additional 2,393,873 common shares were owed to various non-related vendors at December 31, 2022 valued at $ 205,656 based on the fair value of the Company's common stock at the date of board authorization. These shares were not issued through December 31, 2023 and are included in the numbers below.

 Stock payable at December 31, 2023 consists of 16,199,348 preferred shares and 13,177,349 restricted common shares owed to members of the board of directors for directors' fees and contract services. These shares were valued at $ 743,393 based on the fair value of the Company's common stock at the date of board authorization. An additional 7,596,408 common shares were owed to various non-related vendors at December 31, 2023 valued at $ 83,334 based on the fair value of the Company's common stock at the date of board authorization. Subsequent to year end, no issuance of the shares have been made.

 FS-18

 Stock Compensation Plans

 2020 Stock Plan

 On September 25, 2020, the Company adopted the Cannabis Sativa 2020 Stock Plan which authorized the Company to utilize common stock to compensate employees, officers, directors, and independent contractors for services provided to the Company. By resolution dated September 25, 2020, the Company authorized up to 1,000,000 shares of common stock to be issued pursuant to the 2020 Stock Plan. This amount was subsequently increased to 2,000,000 shares on January 27, 2021. At December 31, 2023 and 2022, 44,425 shares were available for future issuance.

 Warrants

 At December 31, 2022, the Company had 50,000 warrants to purchase shares of the Company's common stock. These warrants had an exercise price of $ 2.00 and expired in 2023. During the year ended December 31, 2022, no warrants were issued or exercised and 125,000 warrants expired. During the year ended December 31, 2023, warrants activity consisted of the following: warrants issued - 1,739,766 with an exercise price of $ 0.019 expiring in September 2028.

 7. Commitments and Contingencies

 Leases.

 PrestoCorp leased office space through WeWork in New York on a month-to-month basis which ended in April 2022. On April 12, 2022, PrestoCorp signed a new lease in New York with Spaces for a two-year term at $2,590 per month expiring in April 2024. Upon signing the lease with Spaces, the Company recognized a lease liability and a right of use asset of $ 56,595 using a discount rate of 10 %. The future lease payments under the new lease are as follows:

 From January 1, 2024 to April 30, 2024

 $
 10,360

 Subtotal

 10,360

 Less imputed interest

 ( 128
)

 Net lease liability

 10,232

 Current Portion

 ( 10,232
)

 Long-term portion

 $
 - 0 -

 Rent expense for the years ended December 31, 2023 and 2022 was $ 35,818 and $ 40,720, respectively.

 FS-19

 Litigation.

 In the ordinary course of business, we may face various claims brought by third parties and we may, from time to time, make claims or take legal actions to assert our rights, including intellectual property disputes, contractual disputes and other commercial disputes. Any of these claims could subject us to litigation. As of December 31, 2023, no claims are outstanding.

 8. Proposed Merger with MJ Harvest, Inc.

 On August 8, 2022, the Company entered into a Merger Agreement (the "Merger Agreement") with MJ Harvest, Inc. ("MJHI"). Pursuant to the Merger Agreement, MJHI will merge with and into the Company and the Company will be the surviving corporation in the Merger. The Merger is expected to be consummated once the shareholders of the Company and the shareholders of MJHI approve the Merger which management expects will be completed early in the second quarter of calendar year 2023. The terms of the Merger Agreement are summarized below:

 The name of the surviving company in the Merger will be Cannabis Sativa, Inc.

 Each share of MJHI common stock outstanding on the effective date of the Merger will be converted into 2.7 shares of CBDS Common Stock.

 The Merger is subject to majority approval of the shareholders of both MJHI and CBDS.

 The shareholders of MJHI and CBDS will have rights to dissent from the Merger, and, if the notice of dissent is properly given, the dissenting shareholders may be paid fair value for such dissented shares.

 The Board of Directors of the surviving company following the Merger is intended to consist of Patrick Bilton, Randy Lanier, Clinton Pyatt, and David Tobias.

 The Executive Officers of the Company following the Merger are intended to include Patrick Bilton - Chief Executive Officer, Clinton Pyatt - Chief Operating Officer.

 The Merger Agreement includes representations and warranties, covenants, and conditions for MJHI and CBDS as are customary for transactions of this nature.

 No brokerage fees are payable in connection with the Merger.

 If majority shareholder approval of the merger is not obtained, the Merger will not occur, and the Merger Agreement will be terminated.

 All costs and expenses in connection with the Merger transactions will be borne by CBDS, except that MJHI will be responsible for expenses of its own legal counsel and auditing costs.

 The merger was withdrawn with the SEC in August 2023. The Company and MJ Harvest are continuing discussions in hopes of transaction.

 9. Income Taxes

 The Company did not recognize a tax provision or benefit for the years ended December 31, 2023 and 2022 due to ongoing net losses and a valuation allowance. At December 31, 2023 and 2022, the Company had net deferred tax assets which will not be realized and are fully reserved by valuation allowances.

 At December 31, 2023 and 2022, the Company had net deferred tax assets principally arising from net operating loss carryforward for income tax purposes and differences in the carrying values of goodwill and intangibles between the Company's financial statements and its income tax returns. As management of the Company cannot determine that it is more likely than not that the Company will realize the benefit of the deferred tax assets, a valuation allowance equal to 100% of the net deferred tax asset exists at December 31, 2023 and 2022.

 FS-20

 The components of the Company's net deferred tax assets at December 31, 2023 and 2022 are as follows:

 2023

 2022

 Deferred tax asset:

 Net operating loss carryforwards

 $
 4,198,000

 $
 3,981,000

 Intangibles and goodwill

 1,004,000

 1,036,000

 Investments

 34,000

 66,000

 Other

 ( 6,000
)

 ( 3,000
)

 Total deferred tax assets

 5,230,000

 5,080,000

 Valuation allowance

 ( 5,230,000
)

 ( 5,080,000
)

 Net deferred tax assets

 $
 -

 $
 -

 At December 31, 2023, the Company had net operating loss carry forwards of approximately $ 20,000,000 for federal and state purposes, $ 10,000,000 of which expire between 2024 through 2040. The remaining balance of $10,000,000 will never expire but utilization is limited to 80% of taxable income in any future year.

 The reconciliation of the federal income tax rate and the Company's tax provision (benefit) at December 31, 2023 is as follows:

 2023

 2022

 Provision (benefit) computed using the statutory rate:

 $
 ( 265,000
)

 $
 ( 247,000
)

 Permanent differences

 ( 15,000
)

 10,000

 Change in estimate

 130,000

 18,000

 Change in valuation allowance

 150,000

 219,000

 Total income tax provision (benefit)

 $
 -

 $
 -

 The Company has analyzed its filing positions in all jurisdictions where it is required to file income tax returns and found no positions that would require a liability for uncertain income tax benefits to be recognized. The Company is subject to possible tax examinations for the fiscal years 2020 through 2023. Prior year tax attributes could be adjusted by taxing authorities. If applicable, the Company will deduct interest and penalties as interest expense on the financial statements.

 FS-21

 10. Revision of Previously Issued Financial Statements for Immaterial Misstatement

 During 2023, we determined that the amount of bonus payable to the directors of Presto was understated at December 31, 2022 by $88,200. Wages and salaries expense was understated by $88,200 as a result of this error.

 We assessed the materiality of the effect of the errors on our prior financial statements, both quantitatively and qualitatively, in accordance with the SEC's Staff Accounting Bulletin ("SAB") No. 99, "Materiality," and SAB No. 108, "Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements," and concluded the error was not material to any of our previously issued financial statement. Consequently, we will correct these errors prospectively and revise our financial statements when the consolidated balance sheet, statements of operations and cash flows for such prior period are included in future filings. The revision had no net impact on our sales or net cash provided by operating activities for any period presented. The following tables present a summary of the impact, by financial statement line item, of the revision as of and for the year ended December 31, 2022.

 As Previously

 As

 Reported

 Adjustment

 Revised

 Consolidated Balance Sheet

 Total Current Assets

 $
 477,303

 $
 477,303

 Total Assets

 Total Current Liabilities

 469,721

 $

 557,921

 Total Liabilities

 898,109

 986,309

 Total Stockholders' Equity

 1,672,682

 ( 88,200
)

 1,584,482

 Total Liabilities & Stockholders' Equity

 -

 Consolidated Statement of Operations

 Wages and Salaries expense

 759,054

 847,254

 Loss from Operations

 ( 1,315,070
)

 ( 88,200
)

 ( 1,403,270
)

 Net Loss

 ( 1,174,637
)

)

)

 Net Loss from Operations attributable to non-controlling interest - PrestoCorp

 ( 47,536

)

 -

 ( 47,536

)

 Net Loss from Operations attributable to Cannabis Sativa, Inc.

 ( 1,127,101
)

 ( 88,200
)

 ( 1,215,301
)

 Consolidated Statement of Cash Flows

 Net Loss

 ( 1,174,637
)

 ( 88,200
)

)

 Net Cash Used in Operating Activities

 $
 ( 235,559
)

 $
 -

 $
 ( 235,559
)

 FS-22